Search

Displaying results 991 - 1000 of 5300 in total
  1. Drug

    Parsaclisib

    go.drugbank.com/drugs/DB14867
    Investigational

    Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

  2. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade.

  3. Drug

    Cefuroxime

    go.drugbank.com/drugs/DB01112
    ApprovedInvestigational

    Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

    Products: CEFUROXIMA EG
  4. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … [A189168] To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed.

  5. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    [A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life.

  6. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim alfa can

  7. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … contrast to another RSV vaccine, [respiratory syncytial virus vaccine, adjuvanted] (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration of an

  8. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  9. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  10. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427]. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.